Synapse - Martin Voss

Search Within

Martin Henner Voss

Results (294)

Associations between pretreatment body composition features and clinical outcomes among patients with metastatic clear cell renal cell carcinoma treated with immune checkpoint blockade

Journal Article

Ged, Y.; Sanchez, A.; Patil, S.; Knezevic, A.; Stein, E.; Petruzella, S.; Weiss, K.; Duzgol, C.; Chaim, J.; Akin, O.; more...
Clinical Cancer Research (2022)

Fulltext@MSK | Save

Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN + PEMBRO) or sunitinib (SUN) in the CLEAR study

Meeting Abstract

Voss, M. H.; Powles, T.; McGregor, B. A.; Porta, C.; Grünwald, V.; Merchan, J. R.; Rolland, F.; Maroto-Rey, P.; Goh, J. C.; Xing, D.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Long-term outcomes of adrenal insufficiency (AI) due to anti-PD(L)-1 immune checkpoint inhibitors (ICI) among patients with cancer

Meeting Abstract

Nguyen, B.; Shah, N. J.; Knezevic, A.; Newman, S.; Fitzgerald, K. N.; Kotecha, R.; Lee, C. H.; Carlo, M. I.; Aggen, D. H.; Feldman, D. R.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Molecular profile and clinical outcomes of renal cell carcinoma brain metastases treated with stereotactic radiosurgery

Meeting Abstract

Ma, J.; del Balzo, L.; Khaleel, S. S.; Flynn, J.; Zhang, Z.; Voss, M. H.; Freeman, B.; Hakimi, A. A.; Lee, C. H.; Eichholz, J.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

A robust, trial-agnostic gene signature for response to tyrosine kinase inhibition in ccRRCC

Meeting Abstract

Khaleel, S. S.; Liu, M.; Kuo, F.; Kotecha, R.; Lee, C. H.; Voss, M. H.; Motzer, R. J.; Hakimi, A. A.; Reznik, E.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Progression-free survival after second line of therapy (PFS-2) for metastatic clear cell renal cell carcinoma (ccRCC) in patients treated with first-line immunotherapy combinations

Meeting Abstract

Fitzgerald, K. N.; Duzgol, C.; Knezevic, A.; Shapnik, N.; Kotecha, R.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

STARLITE 2: Phase 2 study of nivolumab plus (177)Lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)

Meeting Abstract

Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Lee, C. H.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Safety and clinical activity of MEDI5752, a PD-1/CTLA-4 bispecific checkpoint inhibitor, as monotherapy in patients (pts) with advanced renal cell carcinoma (RCC): Preliminary results from an FTIH trial

Meeting Abstract

Albiges, L.; Rodriguez, L. M.; Kim, S. W.; Im, S. A.; Carcereny, E.; Rha, S. Y.; Tran, B.; Oliveira, J.; Maroto-Rey, P.; Su, W. C.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

A targetable myeloid inflammatory state governs disease recurrence in clear-cell renal cell carcinoma

Journal Article

Rappold, P. M.; Vuong, L.; Leibold, J.; Chakiryan, N. H.; Curry, M.; Kuo, F.; Sabio, E.; Jiang, H.; Nixon, B. G.; Liu, M.; more...
Cancer Discovery (2022)

Fulltext@MSK | Save

Phase II trial of cabozantinib plus nivolumab in patients with non-clear-cell renal cell carcinoma and genomic correlates

Journal Article

Lee, C. H.; Voss, M. H.; Carlo, M. I.; Chen, Y. B.; Zucker, M.; Knezevic, A.; Lefkowitz, R. A.; Shapnik, N.; Dadoun, C.; Reznik, E.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save